By Josh White
Date: Friday 11 Oct 2024
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced an extension to its timeline for submitting supplemental information to the US Centers for Medicare and Medicaid Services in support of coverage determination for its 'Tutivia' test.
By Josh White
Date: Monday 01 Jul 2024
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced a significant milestone achievement under its agreement with Thermo Fisher Scientific on Monday.
By Josh White
Date: Tuesday 15 Feb 2022
(Sharecast News) - Clinical diagnostics developer Verici Dx announced on Tuesday that its two lead in-vitro diagnostic assays, 'Clarava' and 'Tuteva', had completed analytical validation under the CLIA requirements, meeting criteria for robust assay performance.
Currency | UK Pounds |
Share Price | 2.63p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 11.75 |
52 Week Low | 2.63 |
Volume | 135,120 |
Shares Issued | 242.54m |
Market Cap | £6.37m |
Beta | 0.22 |
RiskGrade | 429 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
15:57 | 10,823 @ 2.69p |
15:36 | 3,040 @ 2.69p |
12:09 | 50,000 @ 2.72p |
11:43 | 34,705 @ 2.72p |
08:35 | 18,203 @ 2.73p |
You are here: research